Abstract
Glycogen synthase kinase 3 (GSK-3) inhibitors have aroused a great interest for medicinal chemists and pharmaceutical companies in the last years. In fact, some candidates have reached to clinical trials as disease modifying drugs for Alzheimer’s disease. This review will cover the great improvements recently done in the field of GSK-3 inhibitors switching from random discovery to rational drug design, from full GSK-3 inhibition to mild and controlled activity of enzyme reduction, from unknown therapeutic potential to validated efficacy in different animal models of diseases. Moreover some lessons learnt from clinical trials will be described with the aim to improve future designs. Collective results highlight the importance of mild GSK-3 inhibitors as innovative drugs for severe human unmet diseases.
Keywords: GSK-3 inhibitors, neurodegenerative diseases, Alzheimer’s disease, clinical trials, drug design.
Current Topics in Medicinal Chemistry
Title:Lessons Learnt from Glycogen Synthase Kinase 3 Inhibitors Development for Alzheimer’s Disease
Volume: 13 Issue: 15
Author(s): Ana Martinez, Daniel I. Perez and Carmen Gil
Affiliation:
Keywords: GSK-3 inhibitors, neurodegenerative diseases, Alzheimer’s disease, clinical trials, drug design.
Abstract: Glycogen synthase kinase 3 (GSK-3) inhibitors have aroused a great interest for medicinal chemists and pharmaceutical companies in the last years. In fact, some candidates have reached to clinical trials as disease modifying drugs for Alzheimer’s disease. This review will cover the great improvements recently done in the field of GSK-3 inhibitors switching from random discovery to rational drug design, from full GSK-3 inhibition to mild and controlled activity of enzyme reduction, from unknown therapeutic potential to validated efficacy in different animal models of diseases. Moreover some lessons learnt from clinical trials will be described with the aim to improve future designs. Collective results highlight the importance of mild GSK-3 inhibitors as innovative drugs for severe human unmet diseases.
Export Options
About this article
Cite this article as:
Martinez Ana, Perez I. Daniel and Gil Carmen, Lessons Learnt from Glycogen Synthase Kinase 3 Inhibitors Development for Alzheimer’s Disease, Current Topics in Medicinal Chemistry 2013; 13 (15) . https://dx.doi.org/10.2174/15680266113139990138
DOI https://dx.doi.org/10.2174/15680266113139990138 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
AlphaFold in Medicinal Chemistry: Opportunities and Challenges
AlphaFold, a groundbreaking AI tool for protein structure prediction, is revolutionizing drug discovery. Its near-atomic accuracy unlocks new avenues for designing targeted drugs and performing efficient virtual screening. However, AlphaFold's static predictions lack the dynamic nature of proteins, crucial for understanding drug action. This is especially true for multi-domain proteins, ...read more
Artificial intelligence for Natural Products Discovery and Development
Our approach involves using computational methods to predict the potential therapeutic benefits of natural products by considering factors such as drug structure, targets, and interactions. We also employ multitarget analysis to understand the role of drug targets in disease pathways. We advocate for the use of artificial intelligence in predicting ...read more
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Clinical Implication of Meissner’s Corpuscles
CNS & Neurological Disorders - Drug Targets Current Advances in L-DOPA and DOPA-Peptidomimetics: Chemistry, Applications and Biological Activity
Current Medicinal Chemistry Multi-Target-Directed Ligands and other Therapeutic Strategies in the Search of a Real Solution for Alzheimer’s Disease
Current Neuropharmacology Speech Recognition Using Elman Artificial Neural Network and Linear Predictive Coding
Recent Advances in Computer Science and Communications Astrocytes Exert and Control Immune Responses in the Brain
Current Immunology Reviews (Discontinued) The Brain Epinephrine-α1-Adrenoceptor System in Behavioral Activation and Depression
Current Psychiatry Reviews Levetiracetam in Compare to Sodium Valproate for Prophylaxis in Chronic Migraine Headache: A Randomized Double-Blind Clinical Trial
Current Clinical Pharmacology Green Tea (Camellia sinensis) Protects Against Arsenic Neurotoxicity via Antioxidative Mechanism and Activation of Superoxide Dismutase Activity
Central Nervous System Agents in Medicinal Chemistry Synthesis and Antiproliferative Activity of New Coumarin-Based Benzopyranone Derivatives Against Human Tumor Cell Lines
Medicinal Chemistry Hypertensive Heart Disease and the Role of Aldosterone Antagonists
Current Hypertension Reviews Editorial (Thematic Issue: Immunotherapy in Central Nervous System)
Current Pharmaceutical Biotechnology Medicinal Plants for the Treatment of Hair Loss and the Suggested Mechanisms
Current Pharmaceutical Design Boosting Interleukin-10 Production: Therapeutic Effects and Mechanisms
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Sleep-Disordered Breathing and Cardiovascular Disease: Exploring Pathophysiology and Existing Data
Current Respiratory Medicine Reviews Presentation of Lipid Antigens by CD1 Glycoproteins
Current Pharmaceutical Design Molecular Docking: Challenges, Advances and its Use in Drug Discovery Perspective
Current Drug Targets Stable Gastric Pentadecapeptide BPC 157: Novel Therapy in Gastrointestinal Tract
Current Pharmaceutical Design Improvement of the Mechanical and Thermal Properties of Bayfol CR6-2 Polymer using UV Radiation
Recent Patents on Mechanical Engineering Interaction of Small Cationic Peptides with Intact Basement Membranes. A Study Using Intrinsic Optical Signals of Chick Retinas
Current Medicinal Chemistry The First Case Report of Kabuki Syndrome from the National Iranian Registry of Primary Immunodeficiencies
Endocrine, Metabolic & Immune Disorders - Drug Targets